Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 500 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 500 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $24.00, for a total transaction of $12,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,477,373 shares in the company, valued at $35,456,952. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Todd Harris also recently made the following trade(s):

• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.01, for a total value of $14,406.00.
• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total value of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Trading Down 2.0 %

TYRA stock traded down $0.46 during midday trading on Wednesday, hitting $22.38. The stock had a trading volume of 146,353 shares, compared to its average volume of 148,159. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -13.32 and a beta of 1.01. Tyra Biosciences, Inc. has a 52 week low of $10.38 and a 52 week high of $25.14. The stock has a 50-day simple moving average of $21.70 and a 200 day simple moving average of $18.94.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. On average, equities analysts forecast that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wedbush reissued an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. Oppenheimer boosted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Finally, Piper Sandler began coverage on Tyra Biosciences in a research note on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of TYRA. HighVista Strategies LLC acquired a new position in shares of Tyra Biosciences during the 2nd quarter worth $257,000. Rhumbline Advisers grew its stake in Tyra Biosciences by 12.3% during the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after purchasing an additional 2,574 shares during the period. Bank of New York Mellon Corp increased its stake in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after purchasing an additional 14,352 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Tyra Biosciences during the 1st quarter worth approximately $977,000. Finally, Wellington Management Group LLP grew its holdings in shares of Tyra Biosciences by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after buying an additional 8,324 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.